1. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia
- Author
-
Martyna Dworaczek, Marta Panz-Klapuch, Kinga Boral, Miroslaw Markiewicz, Anna Armatys, Anna Koclęga, Krzysztof Woźniczka, Anna Kopińska, Grzegorz Helbig, and Karolina Chromik
- Subjects
0301 basic medicine ,Oncology ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Antimetabolites, Antineoplastic ,Azacitidine ,Chronic myelomonocytic leukemia ,Pathology and Forensic Medicine ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,hemic and lymphatic diseases ,Medicine ,Results ,Humans ,In patient ,neoplasms ,Aged ,Retrospective Studies ,Aged, 80 and over ,Acute myeloid leukemia ,business.industry ,Myelodysplastic syndromes ,Myeloid leukemia ,Leukemia, Myelomonocytic, Chronic ,General Medicine ,Middle Aged ,medicine.disease ,Real life data ,Survival Rate ,Regimen ,Leukemia, Myeloid, Acute ,030104 developmental biology ,Treatment Outcome ,030220 oncology & carcinogenesis ,Myelodysplastic Syndromes ,Dose reduction ,Original Article ,Female ,Safety ,business ,Myelodysplastic syndrome ,medicine.drug ,Follow-Up Studies - Abstract
The administration of azacitidine (AZA) was found to be more effective than conventional care regimen (CCR) in patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) with lower blast count. We designed a study to determine efficacy and safety of AZA therapy in “real life” patients with MDS, CMML and AML. The study included 83 patients (65% male) with a median age at diagnosis of 68 years. 43 patients were diagnosed with higher-risk MDS, 30 had AML and 10-CMML. Median AZA dose was comparable between treated groups. AZA dose reduction was required for 44% of MDS, 17% of AML and 25% of CMML patients. Complete remission (CR) was achieved in 14% of MDS, 7% of AML and 10% of CMML patients. Overall response rate was following: 27% for MDS, 20% for AML and 20% for CMML. Estimated OS at 12 months was 75% for MDS, 60% for AML and 75% for CMML. Median follow-up for MDS/AML/CMML from AZA initiation to last follow-up was 9.0, 9.4 and 9.4 months, respectively. The most common toxicity of AZA therapy was myelosuppression and infections. AZA treatment was effective in a limited number of patients with acceptable safety profile.
- Published
- 2019